First Time Loading...

AxoGen Inc
NASDAQ:AXGN

Watchlist Manager
AxoGen Inc Logo
AxoGen Inc
NASDAQ:AXGN
Watchlist
Price: 7.77 USD 2.91% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. [ Read More ]

The intrinsic value of one AXGN stock under the Base Case scenario is 12.4 USD. Compared to the current market price of 7.77 USD, AxoGen Inc is Undervalued by 37%.

Key Points:
AXGN Intrinsic Value
Base Case
12.4 USD
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AxoGen Inc

Backtest AXGN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AXGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Company Revenue Jumps 18.7%, Aiming 11-14% Growth
2023-Q4 Earnings Call

Company Revenue Jumps 18.7%, Aiming 11-14% Growth

The company announced a revenue of $42.9 million for the quarter, marking an 18.7% increase from the previous year. This boost was due to a 10.5% increase in unit volume, a 4.9% improvement in product mix, and a 3.3% rise in pricing. Growth was particularly strong in scheduled procedures, which surged over 25%, while emergent trauma, accounting for about half the revenue, grew by a mid-single-digit percentage. Gross profit climbed to $33.8 million from $30 million, but gross margin fell from 83% to 78.7%, largely due to new facility costs. Operating expenses rose 3.7% to $37 million as sales and marketing expenses grew 11.6% to $22.2 million. However, sales productivity improved, and R&D costs upped by 7.2% to $7.3 million due to regulatory submission costs. The company concluded the quarter with a net loss of $3.9 million, improved from a prior $5.4 million loss, and presented 2024 revenue guidance anticipating a growth rate of 11% to 14%.

Financials

Balance Sheet Decomposition
AxoGen Inc

Current Assets 88m
Cash & Short-Term Investments 31m
Receivables 25.1m
Other Current Assets 31.8m
Non-Current Assets 108.8m
PP&E 104.3m
Intangibles 4.5m
Current Liabilities 30.4m
Accounts Payable 11.8m
Accrued Liabilities 18.7m
Other Current Liabilities 6k
Non-Current Liabilities 70.7m
Long-Term Debt 46.6m
Other Non-Current Liabilities 24.1m
Efficiency

Earnings Waterfall
AxoGen Inc

Revenue
159m USD
Cost of Revenue
-34.2m USD
Gross Profit
124.8m USD
Operating Expenses
-146.2m USD
Operating Income
-21.5m USD
Other Expenses
-254k USD
Net Income
-21.7m USD

Free Cash Flow Analysis
AxoGen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AXGN Profitability Score
Profitability Due Diligence

AxoGen Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
28/100
Profitability
Score

AxoGen Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

AXGN Solvency Score
Solvency Due Diligence

AxoGen Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
40/100
Solvency
Score

AxoGen Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AXGN Price Targets Summary
AxoGen Inc

Wall Street analysts forecast AXGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXGN is 13.94 USD with a low forecast of 11.11 USD and a high forecast of 17.85 USD.

Lowest
Price Target
11.11 USD
43% Upside
Average
Price Target
13.94 USD
79% Upside
Highest
Price Target
17.85 USD
130% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AXGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AXGN Price
AxoGen Inc

1M 1M
-25%
6M 6M
+54%
1Y 1Y
-14%
3Y 3Y
-59%
5Y 5Y
-62%
10Y 10Y
+171%
Annual Price Range
7.77
52w Low
3.61
52w High
10.69
Price Metrics
Average Annual Return -14.58%
Standard Deviation of Annual Returns 20.29%
Max Drawdown -86%
Shares Statistics
Market Capitalization 335.1m USD
Shares Outstanding 43 210 000
Percentage of Shares Shorted 3.51%

AXGN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

AxoGen Inc Logo
AxoGen Inc

Country

United States of America

Industry

Health Care

Market Cap

335.1m USD

Dividend Yield

0%

Description

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.

Contact

FLORIDA
Alachua
13631 Progress Blvd Ste 400
+13864626817.0
https://www.axogeninc.com/

IPO

1986-12-17

Employees

428

Officers

Chairman, President & CEO
Ms. Karen Zaderej
Vice President of Operations
Mr. Michael Donovan
Chief Research & Development Officer
Mr. Angelo G. Scopelianos Ph.D.
Chief Financial Officer
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.
Director of Investor Relations
Ed Joyce
Executive VP, General Counsel & Chief Compliance Officer
Mr. Marc A. Began
Show More
Vice President of Sales
Ms. Doris Quackenbush
Chief Marketing Officer
Mr. Jens Schroeder Kemp
Chief Innovation Officer
Mr. Erick DeVinney
Chief Medical Officer
Dr. Ivica Ducic M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AXGN stock?

The intrinsic value of one AXGN stock under the Base Case scenario is 12.4 USD.

Is AXGN stock undervalued or overvalued?

Compared to the current market price of 7.77 USD, AxoGen Inc is Undervalued by 37%.